

Axonics to Present at the J.P. Morgan Healthcare Conference

December 27, 2023 at 4:01 PM EST

IRVINE, Calif.--(BUSINESS WIRE)--Dec. 27, 2023-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.

Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the <u>2023</u> Financial Times list of the fastest growing companies in the Americas after being ranked No. 1 in <u>2022</u>.

Axonics[®] sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid [®], provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit <u>www.axonics.com</u>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231227494865/en/

Neil Bhalodkar 949-336-5293 IR@axonics.com

Source: Axonics, Inc.